Needham Gives a Hold Rating to LivaNova PLC

By Jason Carr

In a report released today, Michael Matson from Needham assigned a Hold rating to LivaNova PLC (NASDAQ: LIVN). The company’s shares closed yesterday at $65.12, close to its 52-week high of $66.67.

Matson said:

“LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution.”

According to, Matson is a 5-star analyst with an average return of 12.2% and a 64.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

LivaNova PLC has an analyst consensus of Moderate Buy, with a price target consensus of $72.75.

LivaNova PLC’s market cap is currently $3.15B and has a P/E ratio of 114.25. The company has a book value ratio of 1.7013.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LivaNova Plc is a global medical technology company specializing in the areas of Cardiac Surgery, Neuromodulation and Cardiac Rhthym Management. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.